Purification and characterization of Epstein-Barr virus gp340/220 produced by a bovine papillomavirus virus expression vector system.
dc.contributor.author | Madej, Monika | |
dc.contributor.author | Conway, Margaret J | |
dc.contributor.author | Morgan, A J | |
dc.contributor.author | Sweet, J | |
dc.contributor.author | Wallace, L | |
dc.contributor.author | Qualtiere, L F | |
dc.contributor.author | Arrand, John R | |
dc.contributor.author | Mackett, Mike | |
dc.date.accessioned | 2010-08-03T08:18:34Z | |
dc.date.available | 2010-08-03T08:18:34Z | |
dc.date.issued | 1992 | |
dc.identifier.citation | Purification and characterization of Epstein-Barr virus gp340/220 produced by a bovine papillomavirus virus expression vector system. 1992, 10 (11):777-82 Vaccine | en |
dc.identifier.issn | 0264-410X | |
dc.identifier.pmid | 1332270 | |
dc.identifier.doi | 10.1016/0264-410X(92)90513-J | |
dc.identifier.uri | http://hdl.handle.net/10541/108874 | |
dc.description.abstract | Our initial results with a bovine papilloma virus (BPV) vector expression system indicated that we could produce significant amounts of Epstein-Barr virus (EBV) gp340/220 in the supernatant of a mouse fibroblast cell line. We have now extended these findings to show that the truncated version of gp340/220, where the membrane anchor sequence is deleted, is produced even after extended passage of the cells, at a level of approximately 1 mg/4 x 10(8) cells. A simple purification protocol using Sephacryl S300HR and gelatin agarose gives a product which is greater than 90% pure. This product is recognized by anti-gp340 monoclonal antibodies from five different epitope groups and induces antibody that recognizes the authentic gp340/220 and neutralizes EBV in vitro. The purified gp340/220 can be used in ELISA and stimulates the proliferation of T-cell clones specific for gp340/220. These characteristics, together with the fact that BPV-transformed lines have been utilized for the production of pharmaceuticals for use in humans, suggest that this gp340/220 is suitable as a source of antigen for vaccination to prevent EBV infection and related diseases. | |
dc.language.iso | en | en |
dc.subject.mesh | Animals | |
dc.subject.mesh | Antibodies, Viral | |
dc.subject.mesh | Antigens, Viral | |
dc.subject.mesh | Bovine papillomavirus 1 | |
dc.subject.mesh | Clone Cells | |
dc.subject.mesh | Fibroblasts | |
dc.subject.mesh | Gene Expression Regulation | |
dc.subject.mesh | Genetic Vectors | |
dc.subject.mesh | Lymphocyte Activation | |
dc.subject.mesh | Membrane Proteins | |
dc.subject.mesh | Mice | |
dc.subject.mesh | Mice, Inbred BALB C | |
dc.subject.mesh | T-Lymphocytes | |
dc.subject.mesh | Viral Envelope Proteins | |
dc.subject.mesh | Viral Matrix Proteins | |
dc.title | Purification and characterization of Epstein-Barr virus gp340/220 produced by a bovine papillomavirus virus expression vector system. | en |
dc.type | Article | en |
dc.contributor.department | Department of Molecular Biology, Paterson Institute for Cancer Research, Manchester, UK. | en |
dc.identifier.journal | Vaccine | en |
html.description.abstract | Our initial results with a bovine papilloma virus (BPV) vector expression system indicated that we could produce significant amounts of Epstein-Barr virus (EBV) gp340/220 in the supernatant of a mouse fibroblast cell line. We have now extended these findings to show that the truncated version of gp340/220, where the membrane anchor sequence is deleted, is produced even after extended passage of the cells, at a level of approximately 1 mg/4 x 10(8) cells. A simple purification protocol using Sephacryl S300HR and gelatin agarose gives a product which is greater than 90% pure. This product is recognized by anti-gp340 monoclonal antibodies from five different epitope groups and induces antibody that recognizes the authentic gp340/220 and neutralizes EBV in vitro. The purified gp340/220 can be used in ELISA and stimulates the proliferation of T-cell clones specific for gp340/220. These characteristics, together with the fact that BPV-transformed lines have been utilized for the production of pharmaceuticals for use in humans, suggest that this gp340/220 is suitable as a source of antigen for vaccination to prevent EBV infection and related diseases. |